“As early investors in Ultivue, we remain impressed by the differentiation InSituPlex® and the company’s software technologies like Ultistacker® offer to the rapidly expanding field of spatial biology,” said Andrea Jackson, Partner at Northpond Ventures.
In addition to its financing, Ultivue also announced the hire of Rob Carson as President and Chief Executive Officer. Mr. Carson brings more than 20 years of life sciences industry experience, including in the areas of commercial leadership, strategy and transformation, R&D and operations. He previously held GM and other executive roles at Medtronic plc, Waters Corporation and Harbinger Health.
“We’re pleased to welcome Rob to the Ultivue board and as the company’s new CEO. We’re committed to partnering with the Ultivue team as it executes its plan for customer success and continued company growth,” said Keith Crandell, co-founder and Managing Director at ARCH Venture Partners.
Mr. Carson added, “I’m excited to join Ultivue and particularly by the company’s core of passion and expertise. Leveraging InSituPlex® and our proprietary AI capabilities, we have the opportunity to speed the development process of novel therapeutics and to provide unrivaled signal-to-noise performance for our biopharma, CRO and academic partners studying proteins in their spatial context.”
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at ultivue.com.Eva Categories: News Tags: Announcement